Body Health Care

PhotOral will create first intraoral device using blue light as non-invasive weapon against pathogenic bacteria

BOSTON, /PRNewswire/ — Life sciences startupPhotOralannounced today it has licensed a patented technology from Harvard-affiliated Forsyth Institute to develop a novel intraoral device that uses blue light for targeting and obliterating potentially harmful dental plaque microorganisms.

The agreement empowers newly-launched PhotOral to commercialize Forsyth’s photomedicine portfolio, addressing the $7 billion oral care market.PhotOral Founder and CEO, Stamatis Astra says he’s in the midst of fundraising an initial round to support prototype production, clinical trials, and marketing operations.”Our goal is to have the first intraoral light cleaning device available by late 2012,” explains Astra.”We are honored to be working closely with Forsyth experts to create a portfolio of blue light therapy products, ultimately creating an evolutionary move in the oral care experience.”

Forsyth Institute, the leader in oral and craniofacial research, will conduct PhotOral’s clinical trials. I

Find more info…

Breast cancer researchers report they are heartened by the results of two new studies that show combination therapies might improve survival for women with two different types of advanced tumors.

One of the drugs, everolimus (Afinitor), boosted progression-free survival in women with hormone receptor-positive breast cancer but is not yet approved by the U.S. Food and Drug Administration for this indication. The other drug, pertuzumab, improved survival with HER-2 positive tumors, but has not received any FDA approval.

So, the immediate clinical implications are probably “none,” said Dr.

Find more info…

Amblyopia, or lazy eye, is the most common cause of vision problems in children. Only about one in three kids show physical symptoms. Now, as KING 5′s Jean Enersen shows us, a doctor’s invention is helping catch it much earlier.